Specific metabolic activation of FK973, a new antitumor antibiotic, in L1210 leukemia cells.
スポンサーリンク
概要
- 論文の詳細を見る
FK973 (11-acetyl-8-carbamoyloxymethyl-4-formyl-l4-oxa-1, 11 -diazatetracyclo[7.4.1.O<SUP>2, 7</SUP>O<SUP>10, 12</SUP>]tetradeca-2, 4, 6-trien-6, 9-diyl diacetate), a new substituted dihydrobenzoxazine, has potent cytotoxic and antitumor effects on murine and human tumors in vivo and in vitro, and forms interstrand DNA-DNA and DNA-protein cross-links after being activated in the cytoplasm. In this study, the mechanism(s) by which FK973 is activated in the cytoplasm of in vitro cultured murine L1210 leukemia cells were studied using compounds that affect monoamine oxidase. When the cells were incubated with an antitumor drug and the compounds, tranylcypromine, benzylamine, phenylethylamine and tyramine of the many compounds tested reduced the cytotoxicity of FK973, but not that of mitomycin C or cisplatin. These compounds also suppressed the formation of interstrand DNA-DNA crosslinks with FK973 in the cells, but did not suppress cross-links with mitomycin C or cisplatin. The incorporation of <SUP>14</SUP>C-FK973 into the cells was not affected by these compounds. The results suggest that FK973 is activated by some drug-metabolic system(s) in the cytoplasm to form interstrand DNA-DNA cross-links, and induces cytotoxicity against the cells. This activation of FK973 in the cytoplasm is discussed in connection with the drug-metabolic system(s) in relation to the structures of the compounds.
- 公益社団法人 日本薬理学会の論文
著者
-
Nakamura Takaaki
Department Of Anatomy Shiga University Of Medical Science
-
Shimomura Kyoichi
Department Of Pharmacology Pharmacological Research Laboratories Fujisawa Pharmaceutical Co. Ltd.
-
NAKAMURA Takaaki
Department of Pharmacology, Product Development Laboratories, Fujisawa Pharmaceutical Co., Ltd.
-
MASUDA Kikuo
Department of Pharmacology, Product Development Laboratories, Fujisawa Pharmaceutical Co., Ltd.
関連論文
- Glioblastoma Multiforme in the Left Frontal Lobe Subsequent to Malignant Lymphoma in the Right Orbit : Case Report
- Consecutively Occurring Multiple Fibroadenomas of the Breast Distinguished from Phyllodes Tumors by Clonality Analysis of Stromal Tissue
- Protein-Tyrosine Phosphatase 1B Associates with Insulin Receptor and Negatively Regulates Insulin Signaling without Receptor Internalization
- IMMUNOHISTOCHEMICAL IDENTIFICATION OF KERATIN, INVOLUCRIN, AND EPITHELIAL MEMBRANE ANTIGEN IN PAGET'S DISEASE.
- A mammalian dpy-19 homologue is expressed in GABAergic neurons
- New Antitumor Substances, FR901463, FR901464 and FR901465 II. Activities against Experimental Tumors in Mice and Mechanism of Action
- Anti-cachectic Effect of FK317, a Novel Anti-cancer Agent, in Colon26 and LX-1 Models in Mice
- FK317, a Novel Substituted Dihydrobenzoxazine, Exhibits Potent Antitumor Activity against Human Tumor Xenografts in Nude Mice
- Different Effects of FK317 on Multidrug-resistant Tumor in vivo and in vitro
- Cytotoxic Mechanisms of FK317, a New Class of Bioreductive Agent with Potent Antitumor Activity
- Morphological study of the endotoxin translocation in the ileal epithelium of monkey
- Implication of Sensory Neurons in the Diverse Mechanisms of Adaptive Cytoprotection in the Rat Stomach
- SIGNIFICANCE OF WITHDRAWAL JUMPING RESPONSE IN PREDICTING PHYSICAL DEPENDENCE IN MICE
- Antitumor Effects of Droloxifene, a New Antiestrogen Drug, against 7, 12-Dimethylbenz(a)anthracene-Induced Mammary Tumors in Rats.
- Effects of Quinotolast, a New Orally Active Antiallergic Drug, on Experimental Allergic Models.
- Effect of FK973, a new antitumor antibiotic, on the cell cycle of L1210 cells in vitro.
- The Estrogenic and Antiestrogenic Activities of Droloxifene in Human Breast Cancers.
- Specific metabolic activation of FK973, a new antitumor antibiotic, in L1210 leukemia cells.